Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
Date:10/26/2008

00mg oral dose of linezolid given twice daily for five to ten days in the treatment of ambulatory patients with uSSSI where incision and drainage would not be sufficient therapy. It also sought to evaluate the safety and tolerability profile of these two doses compared to linezolid.

About Uncomplicated Skin and Soft Tissue Infections (uSSSI)

Uncomplicated skin and skin structure infection (uSSSI) is a term used to group a wide range of bacterial skin infections, including common dermatologic diseases such as cellulitis, carbuncles and impetigo. These infections may result from minor skin abrasions or even insect bites. The most common cause of uSSSIs is the bacterial Group A streptococci and S. aureus.

About Radezolid

Radezolid is a novel oxazolidinone that was discovered using Rib-X's proprietary discovery process and was designed to expand the bacterial spectrum and improve the utility of this class of antibiotics relative to the only other oxazolidinone marketed in the world, Zyvox(R) (linezolid). Rib-X is developing both oral and IV formulations for use in serious hospital Gram-positive infections, including those caused by MRSA and linezolid- and vancomycin-resistant enterococci. Radezolid is the subject of a second ongoing Phase 2 clinical trial for community acquired pneumonia (CAP). This compound has been shown to be microbiologically more active than linezolid against Gram-positive organisms, including potent activity against linezolid resistant bacteria, in prior studies.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effe
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015 BioRx, a Diplomat company (NYSE: ... a Top Workplace in 2015 based on a survey held ... Media Group and a Philadelphia -based research ... and was completed by employees across the Greater ... area, with topics ranging from workplace environment to overall organizational ...
(Date:7/7/2015)... 7, 2015 Hill-Rom,s recent announcement that ... in cash and stock means the company can ... to Kalorama Information. The healthcare market researcher said ... device and advanced wound care markets, and is ... lifting devices, and other healthcare equipment. Welch Allyn,s ...
(Date:7/7/2015)... --  ICD-10 Charts ( www.icd10charts.com ) announced today ... officially launched its newest line of ICD-10 preparation ... new 4 Step ICD-10 Implementation Plan.  Both of ... Charts resources and mobile apps, are available to ... the release of these resources, the company has ...
Breaking Medicine Technology:BioRx Named a Top Workplace in 2015 by Enquirer Media 2BioRx Named a Top Workplace in 2015 by Enquirer Media 3Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4
... WIRE)--May 15, 2007 - Synthetic Blood,International, Inc. ... analysis of its Phase IIa study with ... line with preliminary,study results announced in December ... of increasing patients' oxygen,tension levels compared with ...
... WIRE)--May 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SLXP) today ... the Company's products,will be presented at Digestive Disease ... Digestive Disease Week is considered the,largest and most ... Every year it attracts more than 16,000 physicians,researchers ...
Cached Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:7/7/2015)... ... July 07, 2015 , ... An article published June ... how innovation and technology would be the “key factors” in the growth of ... accessibility and affordability, especially in emerging and growing markets. According to the compounding ...
(Date:7/7/2015)... BELLINGHAM, WA (PRWEB) , ... July 07, 2015 , ... ... set to break ground as early as Summer 2015 on a four-acre site in ... dollar project, with the support of city officials and other members of the local ...
(Date:7/7/2015)... , ... July 07, 2015 ... ... convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, ... program, surpassing their original 2015 fundraising goal by nearly $100,000, to help ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... Times highlights rumors about possible facial rejuvenation that have emerged about Hillary Clinton. ... U.S. Secretary of State looks more youthful than she has in some time ...
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased to announce the ... York 11747. The new facility is a state of the art building, located ... Quadrino, the firm's CEO and founder, said, "We are pleased to service our clients ...
Breaking Medicine News(10 mins):Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 2Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 3Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3
... of the Phase 2,clinical trial of R788 (fostamatinib ... lymphoma (NHL) will be presented today at a,plenary ... Hematology (ASH),Meeting. The results affirm preliminary reports ... patients and shows therapeutic benefit in,patients suffering from ...
... weight, instead of dieting, is a good way to keep ... News) -- The holiday season is always extra challenging for ... in the fun without packing on the pounds. , ... Brigham and Women,s Hospital in Boston, recommends trying to simply ...
... December 7, 2008) The largest study ever to ... prevent deadly blood clots in patients with cancer undergoing ... on Sunday, December 7, at 9:30 a.m., during the ... in San Francisco, CA. Additional research being featured at ...
... (SAN FRANCISCO, December 6, 2008) A study assessing the ... a variety of hospital settings will be presented at a ... the 50th Annual Meeting of the American Society of Hematology ... that help determine stroke risk in children with sickle cell ...
... The United States can learn from the Dutch Health Insurance ... Ph.D., in the December issue of the Journal of ... management, policy and community health at The University of Texas ... which discusses universal health care coverage in the Netherlands and ...
... create partnerships with pediatric research institutions around the globe, ... understanding with the department of pediatrics at Tokyo,s Jikei ... the first among Mattel Children,s Hospital,s many planned agreements ... , Signed last month, the UCLAJikei ...
Cached Medicine News:Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 2Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 3Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 4Health News:Holidays Don't Have to Make You Heavier 2Health News:Research highlights new approaches to prevent blood clots 2Health News:Research highlights new approaches to prevent blood clots 3Health News:Research highlights new approaches to prevent blood clots 4Health News:Research highlights new approaches to prevent blood clots 5Health News:Research highlights new approaches to prevent blood clots 6Health News:Research highlights new approaches to prevent blood clots 7Health News:Research highlights new approaches to prevent blood clots 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:UT public health policy expert says US can learn from Dutch universal healthcare coverage 2
... Impulse II lead series are silicon ... extend the longevity of the pacemaker ... The high impedance of the lead ... electrode surface, combined with the elution ...
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Selute Picotip Atrial-J steroid eluting passive fixation lead...
Medicine Products: